20/20 Biolabs, Inc. (AIDX)
Nasdaq · Healthcare · Medical Devices
$0.3524−7.26%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $4.5M
- 52-week range
- $0.331 – $50.00
- 52-week change
- −98.41%
- EPS (trailing)
- −$0.75
Fiscal year to Dec 2025
- Revenue
- $2.0M (+16.71%)
- Net income
- −$3.7M
- Operating margin
- −162.9%
- Diluted EPS
- −$0.76
From the company’s annual report on SEC EDGAR.
About 20/20 Biolabs, Inc.
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
Headquarters: Gaithersburg, United States · 4 employees · 2020biolabs.com